



Assembly Biosciences, Inc.  
Investor Relations Department  
787 7th Avenue 48th Floor  
New York, NY 10019  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

<b>NASDAQ: ASMB</b>	
Last Trade:	23.30
Trade Time:	4:00 PM ET May 22, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	5.00 - 28.18
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Assembly Biosciences, Inc. (Nasdaq: ASMB) is a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and novel approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 21, 2017*  
[Assembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan](#)

*Feb 16, 2017*  
[Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations](#)

*Jan 9, 2017*  
[Allergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs](#)

*Nov 11, 2016*  
[Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting](#)

*Nov 9, 2016*  
[Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection](#)

## Upcoming Events [\[ View all \]](#)

*Jun 7, 2017 10:00 AM ET*  
[Jefferies 2017 Global Healthcare Conference](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 2, 2017*  
[Annual Report \(10-K\)](#)

*Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*May 8, 2017*  
[Quarterly Report \(10-Q\)](#)

*Nov 9, 2016*  
[Quarterly Report \(10-Q\)](#)

*Aug 9, 2016*  
[Quarterly Report \(10-Q\)](#)